- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,139 of 2,219.
| EudraCT Number: 2005-004468-22 | Sponsor Protocol Number: HEAD-STUDIE | Start Date*: 2006-03-31 |
| Sponsor Name:Klinikum der Universität München, Kinderklinik und Poliklinik im Dr. von Haunerschen Kinderspital | ||
| Full Title: HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-tempor... | ||
| Medical condition: Benign epilepsy of childhood with centro-temporal spikes (BECTS) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-003742-16 | Sponsor Protocol Number: IB1001-04 | Start Date*: 2014-04-29 | |||||||||||
| Sponsor Name:Cangene Europe Limited | |||||||||||||
| Full Title: Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients with Severe Hemophilia B | |||||||||||||
| Medical condition: Severe Hemophilia B | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005299-32 | Sponsor Protocol Number: OPHT-110912 | Start Date*: 2013-01-24 | |||||||||||
| Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
| Full Title: Effect of breathing 100% oxygen on brain metabolites measured by 7-Tesla MRI | |||||||||||||
| Medical condition: brain metabolism | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004898-16 | Sponsor Protocol Number: V_1 | Start Date*: 2015-05-27 | |||||||||||
| Sponsor Name:Medizinische Universität Wien | |||||||||||||
| Full Title: A study to investigate (R)-11C-verapamil PET as a predictive biomarker for epilepsy surgery outcome | |||||||||||||
| Medical condition: temporal lobe epilepsy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005895-34 | Sponsor Protocol Number: VER1.0 | Start Date*: 2006-06-05 |
| Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna | ||
| Full Title: Effects of common topical glaucoma therapy on optic nerve head blood flow autoregulation during increased arterial blood pressure and artificially elevated intraocular pressure in healthy humans | ||
| Medical condition: only healthy volunteers are included | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-004463-69 | Sponsor Protocol Number: RadiRet | Start Date*: 2012-12-11 | |||||||||||
| Sponsor Name:Charité – University Medicine Berlin | |||||||||||||
| Full Title: Investigation of Radiation Retinopathy (RadiRet Study) Subtitle: Influence of Lucentis® on radiation retinopathy after irradiation of choroidal melanoma | |||||||||||||
| Medical condition: Patients with retinopathy, due to irradiation in uveal melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003943-32 | Sponsor Protocol Number: DORO001 | Start Date*: 2015-08-06 | |||||||||||
| Sponsor Name:Charité University Medicine Berlin | |||||||||||||
| Full Title: Influence of diabetes control on treatment of diabetic macular edema with ranibizumab | |||||||||||||
| Medical condition: Diabetic macular edema | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001027-20 | Sponsor Protocol Number: CACZ885GDE01T | Start Date*: 2012-04-03 | |||||||||||
| Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension. | |||||||||||||
| Medical condition: adult onset Still's disease (AOSD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-006126-10 | Sponsor Protocol Number: Efalizumab in CTCL | Start Date*: 2008-11-27 |
| Sponsor Name:Charité - University Hospital Berlin | ||
| Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma | ||
| Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000844-56 | Sponsor Protocol Number: TOPAS2011 | Start Date*: 2011-07-12 | |||||||||||
| Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
| Full Title: UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study | |||||||||||||
| Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004466-26 | Sponsor Protocol Number: G1T28-04 | Start Date*: 2017-07-10 | |||||||||||
| Sponsor Name:G1 Therapeutics | |||||||||||||
| Full Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy | |||||||||||||
| Medical condition: Locally recurrent or metastatic Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) SI (Completed) HR (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003168-22 | Sponsor Protocol Number: 2020/0206/HP | Start Date*: 2021-09-02 | |||||||||||
| Sponsor Name:Rouen University Hospital | |||||||||||||
| Full Title: Multicenter, uncontrolled pilot study evaluating the efficacy of eculizumab in the treatment of gemcitabine-induced thrombotic microangiopathies. | |||||||||||||
| Medical condition: Thrombotic microangiopathies induced by gemcitabine | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-007011-85 | Sponsor Protocol Number: 13578 | Start Date*: 2009-12-10 |
| Sponsor Name:Charite Universitätsmedizin Berlin | ||
| Full Title: Topical application of morphine for wound healing and analgesia in patients with painful oral lesions | ||
| Medical condition: Erosive and/or ulcerative Oral Lichen Planus. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-000963-42 | Sponsor Protocol Number: GB29298 | Start Date*: 2014-10-01 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis | |||||||||||||
| Medical condition: Idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000248-91 | Sponsor Protocol Number: BTACH2012 | Start Date*: 2013-01-08 | |||||||||||
| Sponsor Name:Institutt for nevromedisin, NTNU | |||||||||||||
| Full Title: Endoscopic block of the sphenopalatine ganglion with botulinum toxin in intractable cluster headache. Safety issues. | |||||||||||||
| Medical condition: Pharmacological refractory cluster headache with durations of periods of attacks normally more than 2 months | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-002143-16 | Sponsor Protocol Number: CUV023 | Start Date*: 2010-02-04 | |||||||||||
| Sponsor Name:Clinuvel Pharmaceuticals Limited | |||||||||||||
| Full Title: A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar ur... | |||||||||||||
| Medical condition: Solar urticaria (SU) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001581-42 | Sponsor Protocol Number: 17972A | Start Date*: 2018-11-19 | |||||||||||
| Sponsor Name:H. Lunbeck A/S | |||||||||||||
| Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with sc... | |||||||||||||
| Medical condition: schizophrenia with persistent prominent negative symptoms | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Completed) CZ (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010843-15 | Sponsor Protocol Number: CUV026 | Start Date*: 2009-10-09 | |||||||||||
| Sponsor Name:Clinuvel Pharmaceuticals Limited | |||||||||||||
| Full Title: A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light er... | |||||||||||||
| Medical condition: Polymorphic light eruption (PLE) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023790-19 | Sponsor Protocol Number: Monofer-ISS-Blooddonor-01 | Start Date*: 2011-08-29 | |||||||||||
| Sponsor Name:Rigshospitalet, afd. 2034 | |||||||||||||
| Full Title: Et randomiseret, prospektivt, dobbeltblindt, komparativt, placebokontrolleret forsøg med intravenøs indgift af jernisomaltosid 1000 (Monofer®) via infusioner til bloddonorer med jernmangel | |||||||||||||
| Medical condition: Forsøg med intravenøs indgift af jernisomaltosid 1000 (Monofer®) via infusioner til bloddonorer med jernmangel. Dobbelblindet, placebokontrolleret forsøg. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004370-34 | Sponsor Protocol Number: POM-003 | Start Date*: 2018-04-09 | |||||||||||
| Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
| Full Title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy | |||||||||||||
| Medical condition: Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.